Janssen Biotech gives patients
Gut Check with new application
Janssen Biotech, Inc. (Horsham, Pa.) reported the launch of Gut Check, a new platform to help improve disease monitoring for the 1.6 million Americans living with Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel diseases (IBD). Gut Check offers a mobile application for patients and a dashboard for health care professionals, designed to enhance communication between patients and their HCPs.
With Gut Check, people living with IBD can track their daily symptoms and lifestyle habits via the mobile application and share this information in real-time with their health care professionals (HCPs). The application leverages bi-weekly patient-reported outcome surveys validated by the National Institute of Health to help assess progress over time. HCPs can use Gut Check to view their patients' data through a HIPAA-compliant dashboard on their tablet or computer. Using the dashboard, they can filter and compare patient data within their practice, local data and national data.
The Gut Check application is free for individuals living with IBD, and the Gut Check dashboard (to connect with patients) is free for health care professionals.
Exact Imaging releases Pri-mus
for prostate tissue imaging
Exact Imaging (Madison, Wis.) said it introduced Pri-mus, the first Prostate Risk Identification Protocol using Micro-Ultrasound. This new protocol, the first of its kind in prostate ultrasound, aims to set a new standard to facilitate micro-ultrasound-based visualization and stratification of prostate tissue imaging and to best instruct real-time targeting of suspicious regions using the micro-ultrasound platform.
The new Pri-mus protocol using the Exactvu micro-ultrasound platform, is being introduced at the 4th ESUI (European Association of Urology Section of Urological Imaging) Meeting in Barcelona, Spain on Nov. 12, 2015 where it will be presented as part of the Scientific Sessions as well as in a Scientific Poster Session.
The Pri-mus protocol is also being profiled at the ESUI 2015 conference in a scientific poster (P050), titled "Assessing cancer risk in 29 MHz micro-ultrasound images of the prostate: Creation of the Primus (prostate risk identification using micro-ultrasound) protocol", the first scientific presentation that describes the development and evidence-based validation of the Pri-mus protocol.
Researchers discover "Golden
Window" for deep brain imaging
The neuroscience community is saluting the creation of a "Golden Window" for deep brain imaging by researchers at The City College of New York led by biomedical engineer Lingyan Shi. This is a first for brain imaging, said Shi, a research associate in City College's Institute for Ultrafast Spectroscopy and Lasers, and the biology department.
The breakthrough holds promise for the noninvasive study of the brain and breasts in greater detail than possible today.
Working with professor of physics Robert Alfano and Adrian Rodriguez-Contreras, an assistant professor of biology, Shi's team proved theoretically and experimentally that deep imaging of the brain is possible using light at wavelength 1600 to 1880nm (nanometers). This is dubbed the "Golden Window" for imaging.
In the past, near-infrared (NIR) radiation has been employed using one and two-photon fluorescence imaging at wavelengths 650 to 950 nm for deep brain imaging. This is known as optical window.
Shi said the current research introduces three new optical windows in the NIR region. And she demonstrates the windows' potential for deeper brain tissue imaging due to the reduction of scattering that causes blurring. Published by the Journal of Biophotonics, her study sheds light on the development of next generation of microscopy imaging technique, in which the "Golden Window" may be utilized for high resolution deeper brain imaging. The next step in the research is in vivo imaging in mice using Golden Window wavelength light.
Cracking down on
In an opinion piece published in The New England Journal of Medicine, researchers said the recent Institute of Medicine report on "Improving Diagnosis in Health Care" requires individual and collaborative action from all health care stakeholders nationwide.
Diagnostic errors involve several types of missed opportunities to make a correct and timely diagnosis; a diagnosis may be missed completely, the wrong one may be provided, or diagnosis may be delayed, all of which can lead to harm from delayed or inappropriate treatments and tests.
During the past decade, researchers have quantified the issue in a series of studies, many of which were cited in the Institute of Medicine report.
Researchers said that one of the first steps should be for researchers and other safety professionals to develop resources to help institutions and clinicians figure out how to identify and measure diagnostic errors accurately.
The authors also recommended that both patients and practicing clinicians actively engage in generating solutions to reduce misdiagnosis.